14th Jul 2011 14:18
Annual Information Update 2011
BTG plc (LSE:BGC) ("the Company") is pleased to provide its annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months ending today. To avoid an unnecessarily lengthy document, information is referred to in this update rather than included in full.
The information referred to in this update was up to date at the time the information was published but some information may now be out-of-date.
(1) Announcements made via RNS, a Regulatory Information Service
All of the documents listed below were published via RNS, a Regulatory Information Service on or around the dates indicated.
Date of publication | Brief Description of announcement |
14 July 2011 | Notification of major interest in BTG plc shares |
11 July 2011 | Phase 3 Study of Alemtuzumab |
6 July 2011 | BTG acquires US marketing rights to Wellstat's investigational antidote for 5-FU overexposure |
30 June 2011 | Total voting rights and share capital |
22 June 2011 | Notification of submission of documents to the National Storage Mechanism |
15 June 2011 | Additional Listing |
3 June 2011 | Total voting rights and share capital |
2 June 2011 | Directors' Interests in shares of BTG plc |
25 May 2011 | Final Results announcement |
18 May 2011 | Notice of Results |
16 May 2011 | Notification of major interest in BTG plc shares |
13 May 2011 | AstraZeneca ends CM-3 development and option agreement |
12 May 2011 | Notification of major interest in BTG plc shares |
3 May 2011 | ZYTIGA™ (abiraterone acetate) Approved in the US |
26 April 2011 | Notification of major interest in BTG plc shares |
5 April 2011 | Notification of major interest in BTG plc shares |
5 April 2011 | Block Listing Return |
5 April 2011 | Trading Statement |
31 March 2011 | Total voting rights and share capital |
17 March 2011 | Notification of major interest in BTG plc shares |
16 March 2011 | Total voting rights and share capital |
15 March 2011 | Notification of major interest in BTG plc shares |
15 March 2011 | Notification of major interest in BTG plc shares |
11 March 2011 | DEFEND-1 Study of otelixizumab in type 1 diabetes did not meet primary endpoint |
11 February 2011 | Notification of major interest in BTG plc shares |
7 February 2011 | Notification of major interest in BTG plc shares |
2 February 2011 | Notification of major interest in BTG plc shares |
2 February 2011 | Notification of major interest in BTG plc shares |
1 February 2011 | Notification of major interest in BTG plc shares |
1 February 2011 | Notification of major interest in BTG plc shares |
1 February 2011 | Notification of major interest in BTG plc shares |
1 February 2011 | Appointment of Joint Corporate Broker |
31 January 2011 | Notification of major interest in BTG plc shares |
31 January 2011 | Notification of major interest in BTG plc shares |
31 January 2011 | Total voting rights and share capital |
28 January 2011 | Notification of major interest in BTG plc shares |
28 January 2011 | Offer update: Admission of new BTG shares |
27 January 2011 | Acquisition of Biocompatibles International plc. Offer update: Scheme effective |
27 January 2011 | Interim Management Statement |
26 January 2011 | Notification of major interest in BTG plc shares |
24 January 2011 | Offer update: Court sanction of the Scheme of Arrangement and timetable update |
6 January 2011 | Offer update: Result of BTG shareholder meeting |
6 January 2011 | BTG to present at the J.P. Morgan Annual Healthcare Conference |
21 December 2010 | New Drug application submitted in the US and Marketing Authorisation Application filed in the EU for Abiraterone Acetate |
10 December 2010 | Offer Update: Posting of scheme document |
30 November 2010 | Total voting rights and share capital |
29 November 2010 | Director's appointment |
25 November 2010 | Total voting rights and share capital |
24 November 2010 | Total voting rights and share capital |
19 November 2010 | Form 8 Public Opening Position Disclosure by a party to an offer |
19 November 2010 | Form 8 Public Opening Position Disclosure by a party to an offer |
19 November 2010 | Recommended Acquisition of Biocompatibles International plc |
4 November 2010 | Interim results announcement |
29 October 2010 | Total voting rights and share capital |
28 October 2010 | Notification of major interest in BTG plc shares |
25 October 2010 | AstraZeneca initiates Phase IIb study for AZD9773 (Cytofab™) as a treatment for severe sepsis |
20 October 2010 | Notice of results |
15 October 2010 | Genzyme reports positive data on alemtuzumab |
4 October 2010 | Block Listing Return |
4 October 2010 | Total voting rights and share capital |
16 September 2010 | First Varisolve ® US Phase III Trial initiated |
13 September 2010 | Notification of major interest in BTG plc shares |
10 September 2010 | Abiraterone Acetate meets criteria in Cancer study |
1 September 2010 | Directors' Interests in shares of BTG plc |
31 August 2010 | Agreement with Nycomed US Inc |
30 July 2010 | Director's appointment |
21 July 2010 | Directors' Interests in shares of BTG plc |
16 July 2010 | Resolutions passed at the AGM |
16 July 2010 | Appointment of joint financial adviser and corporate broker |
14 July 2010 | Director's retirement |
13 July 2010 | Results of 2010 AGM |
13 July 2010 | AGM and Interim Management Statement |
12 July 2010 | Annual Information Update 2010 |
Copies of the above announcements can be downloaded from the Company's website (www.btgplc.com) or obtained from the Company Secretary at the Company's Registered Office, 5 Fleet Place, London, EC4M 7RD
(2) Documents filed at Companies House
All of the documents listed below were filed with Companies House in Cardiff on or around the dates indicated.
Date of filing | Brief Description of document |
13 June 2011 | Form SH01 Statement of Capital |
31 March 2011 | Form SH01 Statement of Capital |
7 February 2011 | Form TM01 Resignation of William Jenkins as Director |
2 February 2011 | Form SH01 Statement of Capital |
14 January 2011 | Filing of Special resolutions passed at General Meeting |
7 January 2011 | Form AR01 Annual Return |
13 December 2010 | Form SH01 Statement of Capital |
6 December 2010 | Form AP01 Appointment of Melanie Lee as Director |
4 November 2010 | Filing of Company's Objects |
29 October 2010 | Form SH01 Statement of Capital |
4 October 2010 | Form SH01 Statement of Capital |
9 August 2010 | Form AP01 Appointment of Ian Fraser Robert Much as Director |
6 August 2010 | Group Accounts made up to 31 March 2010 |
23 July 2010 | Filing of special resolutions passed at AGM |
20 July 2010 | Filing of special resolutions passed at AGM |
20 July 2010 | Form TM01 Resignation of Colin Blakemore as Director |
Copies of documents filed at Companies House can be obtained from Companies House or obtained from the Company Secretary at the Company's Registered Office. 5 Fleet Place, London EC4M 7RD
CONTACT: Andy Burrows
Director of Investor Relations
Telephone: 020 7575 1741
Related Shares:
BTG